A Lol system-inhibiting compound formulated to kill Gram-negative bacteria, and its effect on the gut microbiota of Clostridium difficile
They are the stuff of medical nightmares. Gram negativebacteria are frequently hardy, virulent and quick to evolve resistance to antibiotics. Only a few drugs can knock them out, and these also destroy beneficial gut bacteria.
The authors of the study began with compounds that do not kill the bacteria, but are known to inhibition theLol system, which is exclusive to Gram-negativebacteria. Paul Hergenrother, co-author of the study, says that they took those compounds and mixed them with some nonpathogenic Escherichia coli to create a type of compound called lolamicin, which is able to kill both pathogenic and nonpathogenic Escherichia coli.
The effects of antibiotic treatment on the gut microbiota and its colonization resistance against Clostridium difficile. mBio 6 was published.
The study proves that targeting the Lol system is viable, but there is still a long way from finding a drug for human use.
Compound entries for discovering Gram-negative antibiotics that spare the gut microbiome: an analysis and a new R package for reproducible interactive analysis and graphics of census data
Hiller sounds cautious. The time from an antibiotic’s discovery to its approval for clinical use can be more than two decades, “and there is not much money to be made with a novel antibiotic”, he says. “Around ten to twenty new Gram-negative antibiotics have been discovered in the last ten years”, he adds, but none has gained approval from the US Food and Drug Administration.
Clearance of Clostridioides difficile colonization is related to changes of antibiotic-specific bacterium. mSphere 6 will be in effect during this time.
The purpose of compound entry is to discover antibiotics for Gram-negativebacteria. Acc. Chem. Res. 54, 1322–1333 (2021).
McMurdie, P. J. & Holmes, S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS ONE 8, e61217 (2013).
Lan, Y., Wang, Q., Cole, J. R. & Rosen, G. L. Using the RDP classifier to predict taxonomic novelty and reduce the search space for finding novel organisms. PLoS ONE 7, e32491 (2012).
Source: A Gram-negative-selective antibiotic that spares the gut microbiome
A short list of numerical results on Langevin equations of motion for molecular-dynamics and applications to the CHARMM additive force field for lipids
A simulation of the Langevin method for constant-pressure molecular-dynamics. J. Chem. The following is a list of Phys. 103’s published in 1995.
The motion of a system with constraints is numerically integrated by the Cartesian equations of motion. J. Comput. Phys. 23, 327–341 (1977).
J. B., Klauda, and others. Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types. J. Phys. The Chem. B 114 was published in 2010.
Hart, K. et al. Optimization of the CHARMM additive force field for DNA: improved treatment of the BI/BII conformational equilibrium. J. Chem. Theor. Comput. 8, 348–362 (2012).
Trott, O. & Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455–461 (2010).
Licari, G., Dehghani-Ghahnaviyeh, S. & Tajkhorshid, E. Membrane Mixer: a toolkit for efficient shuffling of lipids in heterogeneous biological membranes. J. Chem. Inform. Model. 62, 986–996 (2022).
Source: A Gram-negative-selective antibiotic that spares the gut microbiome
Antibacterial effects in a Gram-negative bacteria with cyclic moieties: a comparison of simple potential functions for the simulation of liquid water
There was a comparison of simple potential functions for the simulation of liquid water. J. Chem. Phys. 79, 926–935 (1983).
A model of Escherichia coli with cyclic moieties is presented. A mixture of herbs. There is a science called biophys. Acta 1818, 1205–1210 (2012).
Rana, P. et al. FabI is a potential broad spectrum therapeutic target. A translation of the word Eur. J. Med. Chem. 208, 112757 (2020).
Nickerson, N. N. et al. A novel drug is used to block the ABC transporter for lipoprotein trafficking in Gram negativebacteria. Antimicrob. Agents Chemother. 62, e02151–02117 (2018).
Purnapatre, K. P. et al. In vitro and in vivo activities of DS86760016, a novel leucyl-tRNA synthetase inhibitor for Gram-negative pathogens. Antimicrob. The agents Chemother. 62 was published in the month of October.
Oefner, C. et al. Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity. J. Antimicrob. Chemother. 63 was published in 2009.
Garcia Chavez, M. et al. Synthesis of fusidic acid derivatives give an antibiotic with an improved resistance profile. ACS Infect. The Dis. 7, 493–500, will be in the new year.
Nayar, A. S. et al. A cell wall reporter test reveals antibacterial targets and compounds. J. Bacteriol is a man. 197, 1726–1734 (2015).
Richter, M. F. and Hergenrother, P.J. The challenge of converting Gram positive only compounds into broad-spectrum antibiotics. Ann. NY Acad. Sci. 1435, 18–38 (2019).
Source: A Gram-negative-selective antibiotic that spares the gut microbiome
Outer membrane protein trafficking in Escherichia coli: A novel target of the bacterial lipoprotein target, Pseudomonas aeruginosa
Grabowicz, M. & Silhavy, T. J. Redefining the essential trafficking pathway for outer membrane lipoproteins. Proc. Natl Acad. USA 114, 4769–4774 was published in the journalSci.
R. Pathania and et al. Chemical genomics in Escherichia coli identifies an inhibitor of bacterial lipoprotein targeting. Nat. Chem. 5, 891–856, was published in 2009.
Hoang, H. H. et al. Outer membrane targeting of Pseudomonas aeruginosa proteins shows variable dependence on the components of Bam and Lol machineries. mBio 2 is available
Source: A Gram-negative-selective antibiotic that spares the gut microbiome
The role of thiourea polymers in the evolution of resistance genes of Gram-negative bacteria: a case study on human gut microbiota
Barker, C. A. et al. The interaction of thiourea compounds with the lipoprotein targeting chaperone is being studied. Med. Chem. Lett. 23, 2426–2431 (2013).
Falagas, M. E. & Kasiakou, S. K. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin. Infect. Dis. 40, 1333–1341 was published in 2005.
Human gut microbiota: repertoire and variations, Lagier, J. C., Million, M., Hugon, P., Armougom, F. Front. Cell Infect. Microbiol. 2, 136 (2012).
The long-term persistence of resistant Bacteroides spp. and resistance genes are studied. J. Antimicrob. Chemother. 58, 1160–1167 (2006).